ImmunityBio Faces Class Action Lawsuit Over Fraudulent Drug Promotions Allegations

Investor Alert: ImmunityBio's Legal Troubles

ImmunityBio, Inc. (NASDAQ: IBRX) is currently embroiled in serious legal issues related to its promotional practices regarding the drug ANKTIVA. Investors are being alerted by the law firm Levi & Korsinsky, LLP about a pending securities class action that could significantly affect their investment outcomes. The class action specifically focuses on allegations that ImmunityBio misrepresented ANKTIVA's approved uses and efficacy, leading to considerable financial losses for shareholders.

Background of the Allegations

The legal action stems from a promotional campaign that allegedly mischaracterized ANKTIVA, which is only approved for use in a narrowly defined group of bladder cancer patients. The company's advertisements purportedly suggested that the drug could treat “all cancers,” and function as a cancer vaccine capable of preventing the disease in individuals exposed to radiation. This portrayal vastly overshot the clinical evidence and FDA approval, which strictly limit its application to high-risk, non-muscle invasive bladder cancer patients.

During the lead-up to March 24, 2026, shares of ImmunityBio plummeted by approximately 21%, dropping $1.98 per share to close at $7.42. This decline followed a critical FDA warning letter publicly addressed to the company, which criticized its promotional tactics as being “false or misleading.”

Details of the Lawsuit

According to the lawsuit, ImmunityBio violated numerous advertising regulations associated with the promotion of prescription drugs, particularly in the oncology sector. Key allegations include:
1. Misbranding ANKTIVA by promoting it as an efficacious treatment for all types of cancer without clinical support.
2. Misrepresenting the approved method of administration, as promotional materials solicited the drug's delivery via subcutaneous injection, which is against the prescribing guidelines.
3. Inaccurately branding ANKTIVA as a vaccine with preventive effects and suggesting it could serve as a rescue therapy for lung cancer patients.
4. Non-compliance in submitting promotional podcast content to the FDA for vetting, further exacerbating the situation.

Implications for Investors

The repercussions of these alleged infractions could be significant, not only harming company credibility but also causing tangible financial losses to investors. As Joseph E. Levi of Levi & Korsinsky stated, “Investors deserve transparency about material risks that could affect their investments.” The risks tied to the company’s overstated claims may lead to punitive regulatory consequences, thereby impacting stock performance and investor sentiment.

What Should Affected Investors Do?

For investors who purchased ImmunityBio’s shares during the specified class period from January 19, 2026 to March 24, 2026, the lawsuit presents a potential avenue for recovering losses linked to these misleading promotions. The law firm emphasizes that affected parties should act swiftly by collecting relevant brokerage records to establish the purchase dates and losses incurred.

Prospective participants can reach out to Levi & Korsinsky for a no-cost consultation to evaluate their eligibility for joining the class action lawsuit. Importantly, investors are reminded that their eligibility does not hinge on the current holding status of their shares.

Conclusion

The case against ImmunityBio underscores the necessity for strict adherence to truthful marketing practices within the pharmaceutical industry. As the legal proceedings unfold, it will serve as a critical reminder of the potential consequences companies face when misleading investors and consumers alike. Investors believing they have been negatively affected should stay informed and consider asserting their rights within a legitimate legal framework.

For further assistance, individuals may reach out to the law firm at the provided contact details for guidance on next steps and participation in the lawsuit.